Mar 09 2025 7 mins 11
In this episode of Stock Break, Josh Gilbert discusses Novo Nordisk, the company behind the popular weight loss drugs Ozempic and Wegovy. Josh covers the company's financial performance, including significant revenue growth and the impact of competition from Eli Lilly. The episode also looks at Novo Nordisk's future, emphasising the importance of R&D breakthroughs and the potential of the stock for long-term investors.
Click here to watch on YouTube
This communication is for information and education purposes only and should not be taken as investment advice, a personal recommendation, or an offer of, or solicitation to buy or sell, any financial instruments. This material has been prepared without taking into account any particular recipient’s investment objectives or financial situation, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication.
Click here to watch on YouTube
This communication is for information and education purposes only and should not be taken as investment advice, a personal recommendation, or an offer of, or solicitation to buy or sell, any financial instruments. This material has been prepared without taking into account any particular recipient’s investment objectives or financial situation, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication.
Digest & Invest by eToro is presented by our friends over at: fame.so
